Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Beresford, MD MRCP FRCR
Royal United Hospital NHS Trust, Bath, UK
Study Director - Robert Jones, MD PhD MCRCP
Velindre NHS Trust, Cardiff, UK
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Bournemouth Hospital
Bournemouth, Dorset, United Kingdom
Recruiting - Royal Devon and Exeter Hospital
Exeter, England, United Kingdom
Recruiting - Royal Cornwall Hospital
Truro, Cornwall, England, United Kingdom
Recruiting - Velindre Cancer Center, Velindre Hospital
Cardiff, Wales, United Kingdom
Recruiting - Royal United Hospital Bath
Bath, United Kingdom
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2015
- Primary completion
- 31 Dec 2018
- Completion
- 31 Dec 2020
- Last update posted
- 21 Aug 2015
- Registered enrollment
- 160
- Registry id
- NCT02530411
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.